erlotinib hydrochloride has been researched along with abt-737 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (abt-737) | Trials (abt-737) | Recent Studies (post-2010) (abt-737) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 632 | 0 | 484 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | abt-737 (IC50) |
|---|---|---|---|
| Bcl-2-like protein 11 | Homo sapiens (human) | 0.002 | |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | 0.0206 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | 0.02 | |
| BH3-interacting domain death agonist | Homo sapiens (human) | 0.0485 | |
| Apoptosis regulator BAX | Homo sapiens (human) | 0.023 | |
| Bcl-2-like protein 1 | Homo sapiens (human) | 0.0207 | |
| Induced myeloid leukemia cell differentiation protein Mcl-1 | Homo sapiens (human) | 0.0248 | |
| Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | 3.44 | |
| Bcl-2 homologous antagonist/killer | Homo sapiens (human) | 0.0335 | |
| Bcl-2-like protein 2 | Homo sapiens (human) | 0.0335 | |
| Bcl-2-binding component 3, isoforms 1/2 | Homo sapiens (human) | 0.0003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagai, R; Fan, W; Flask, CA; Fu, P; Hafez-Khayyata, S; Halmos, B; Howell, S; Huang, H; Jiang, S; Koon, H; Kresak, A; Ma, PC; Morrison, B; Tang, Z; Vasanji, A; Yin, L | 1 |
1 other study(ies) available for erlotinib hydrochloride and abt-737
| Article | Year |
|---|---|
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; bcl-X Protein; Biphenyl Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mice; Nitrophenols; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Transplantation, Heterologous | 2011 |